Welcome to our dedicated page for Claritev SEC filings (Ticker: CTEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Claritev Corporation (NYSE: CTEV) files a range of documents with the U.S. Securities and Exchange Commission that detail its operations as a healthcare technology, data and insights company. As an issuer of Class A common stock listed on the New York Stock Exchange, Claritev provides investors with periodic and current reports that describe its financial performance, capital structure, client relationships and key corporate events.
On this page, you can access Claritev’s SEC filings, including current reports on Form 8-K that the company uses to announce material developments. Recent 8-K filings have covered topics such as quarterly financial results, contract renewals with its ten largest clients, underwriting agreements for secondary offerings of Class A common stock by selling stockholders, and changes in executive roles. These filings also confirm that Claritev’s Class A common stock, with a par value of $0.0001 per share, is registered under Section 12(b) and trades under the symbol CTEV on the NYSE.
Claritev’s earnings-related filings and exhibits provide detail on revenues, net income or loss, and non-GAAP metrics such as EBITDA, Adjusted EBITDA, Free Cash Flow, Unlevered Free Cash Flow and an Adjusted cash conversion ratio. The company defines these measures and explains their limitations, giving investors insight into how management evaluates performance and cash generation alongside GAAP results.
Through Stock Titan, these filings are complemented by AI-powered summaries that help explain the significance of each document. Investors can quickly see the key points from Claritev’s 8-Ks, and, where available, review annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy materials and other disclosures. This page also provides a pathway to monitor any insider-related filings, such as Form 4 reports, that may be associated with Claritev’s equity compensation and ownership changes, offering a structured view of the company’s regulatory reporting history.
Claritev Corp (CTEV) reported an insider stock purchase by its SVP and Chief Strategy Officer. On 11/17/2025, the executive bought 916 shares of Class A common stock in an open market transaction at a price of $38 per share, coded as a purchase ("P"). After this transaction, the executive beneficially owned a total of 65,325 shares, all held as a direct ownership position.
Claritev Corp (CTEV) reported a new large shareholder disclosure. Investment manager Arini Capital Management Limited and related entities report beneficial ownership of 1,261,250 Claritev common shares, representing 7.64% of the class. This ownership is calculated based on 10,000,000 Class A ordinary shares referenced from a prior Claritev Form 8-K.
The filing shows Arini Capital Management Limited, its U.S. affiliate, Arini Credit Master Fund Limited, Arini Capital Management Holdings (Jersey) Limited, and individual founder and CIO Hamza M. Lemssouguer as having shared voting and dispositive power over these shares, and no sole power. The certification states that the securities were not acquired and are not held for the purpose of changing or influencing control of Claritev, indicating a passive investment posture.
Claritev Corp (CTEV) executive vice president and chief digital officer reported buying additional company stock. On 11/17/2025, the officer purchased 9,600 shares of Class A common stock in an open-market transaction coded as a purchase at a price of $38.2499 per share. After this transaction, the executive beneficially owns 105,529 shares of Claritev Corp common stock, held directly.
Claritev Corp (CTEV) senior vice president and general counsel reported a small open-market purchase of company stock. On 11/17/2025, the officer acquired 625 shares of Class A common stock at a price of $38.8364 per share, according to a Form 4 filing. Following this transaction, the officer beneficially owns 25,028 shares of Claritev Class A common stock, held directly.
Claritev Corp (CTEV): Hellman & Friedman–affiliated reporting persons disclosed open‑market disposals of Class A common stock tied to an underwritten public offering on 11/12/2025. The shares were sold at a price per share equal to the public offering price, net of underwriting discounts and commissions.
Reported transactions included, for example, a sale of 789,936 shares at $48.6675 per share and additional sales by affiliated funds on the same date. Following the transactions, each affiliated entity reported updated indirect beneficial holdings. The filing identifies the reporting persons as affiliated with Hellman & Friedman funds and indicates indirect ownership across multiple vehicles.
Hellman & Friedman–affiliated funds filed Amendment No. 3 to Schedule 13D on Claritev Corporation (CTEV), reporting aggregate beneficial ownership of 3,887,858 shares, or 23.5% of Class A common stock. The percentage is based on 16,525,644 shares outstanding as of November 3, 2025.
The filing discloses a secondary sale by H&F selling stockholders of 1,500,000 shares at a $51.50 public offering price per share, less a $2.8325 underwriting discount, with an underwriters’ overallotment option for up to 225,000 shares. A 60‑day lock‑up from November 12, 2025 applies to the issuer, directors, officers, the H&F selling stockholders, and others, subject to exceptions.
If the overallotment is exercised, the filing notes beneficial ownership would be 3,662,858 shares, or 22.2%. The funds state investment intent and may buy or sell securities over time, subject to market conditions and agreements referenced.
Claritev Corporation disclosed that affiliates of Hellman & Friedman sold 1,500,000 shares of its Class A common stock in an underwritten secondary offering at $51.50 per share. The Company did not sell any shares and received no proceeds from this transaction.
The Selling Stockholders granted the underwriters a 30-day option to purchase up to 225,000 additional shares. Barclays Capital, Guggenheim Securities, and Wells Fargo Securities acted as joint bookrunners. The offering closed on November 14, 2025. The agreement includes customary representations, warranties, conditions, termination provisions, and indemnification.
Claritev Corporation is registering 1,500,000 shares of its Class A common stock for resale by existing selling securityholders, with underwriters holding an option to purchase up to an additional 225,000 shares. All shares are being sold by current owners, so Claritev will not receive proceeds, though it will cover offering expenses other than underwriting discounts and commissions.
As of September 30, 2025, 16,509,496 shares of Class A common stock were outstanding. The H&F Investors group, which controlled approximately 32.6% of Claritev’s voting equity before this offering, will beneficially own about 23.5% after the base deal, or 22.2% if the underwriters’ option is fully exercised.
Claritev provides data-driven cost management solutions to healthcare payors. Its analytics, network, payment integrity and data science services target lower medical costs and better reimbursement accuracy, and identified approximately $18.6 billion in potential medical cost savings for the nine months ended September 30, 2025.
Claritev Corporation reported Q3 2025 results with revenue of $245,959 thousand, up from $230,495 thousand a year ago. Operating income was $10,067 thousand versus an operating loss last year, while net loss narrowed to $69,753 thousand from $391,450 thousand. Net loss per share was $4.23, adjusted for the 1-for-40 reverse split.
For the first nine months, revenue reached $718,859 thousand versus $698,479 thousand, with operating income of $36,387 thousand and a net loss of $203,712 thousand. Year-to-date operating cash flow was $51,038 thousand. Cash and cash equivalents were $39,152 thousand, plus $11,493 thousand of restricted cash, as of September 30, 2025. Long-term debt (net) was $4,546,671 thousand and shareholders’ deficit was $101,835 thousand. The company completed a January 30, 2025 refinancing, established a $350,000 thousand revolving credit facility (with $70,000 thousand outstanding at quarter end), and recorded interest expense of $101,232 thousand in Q3.
Claritev Corporation furnished a Form 8-K to announce it issued a press release reporting financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information under Item 2.02, including Exhibit 99.1, is furnished and not filed under the Exchange Act and is not subject to Section 18 liability. The filing also lists Exhibit 104 for the cover page Inline XBRL data.